证券代码：300261 证券简称：雅本化学 公告编号：2026-016 雅本化学股份有限公司 关于拟购买董事、高级管理人员责任险的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 雅本化学股份有限公司（以下简称"公司"）于 2026 年 3 月 31 日召开第六届 董事会第九次（临时）会议，审议了《关于为公司及董事、高级管理人员购买责任 保险的议案》。为健全公司治理结构，完善风险管理体系，促进董事、高级管理人 员依法合规、勤勉尽责地履行职责，实现权力、责任和利益的有机统一，根据《中 华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准则》《深圳证 券交易所创业板股票上市规则》等相关规定，公司拟为公司及全体董事、高级管理 人员投保责任保险（以下简称"责任险"），以支持其在履职过程中合理承担相应 责任，提升公司治理效能和决策质量。鉴于公司全体董事均为被保险对象，属于利 益相关方，全体董事均对该议案回避表决，该议案尚需提交公司股东会审议批准。 具体事项公告如下： 一、拟购买的责任险具体方案 1、投保人：公司 2、被投保人：公司及其董事、高级管理人员（具 ...

证券代码：300261 证券简称：雅本化学 公告编号：2026-015 雅本化学股份有限公司 第六届董事会第九次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 雅本化学股份有限公司（以下简称"公司"）第六届董事会第九次（临时）会 议于 2026 年 3 月 31 日上午 10:30 以现场结合通讯方式召开，会议通知已于 2026 年 3 月 26 日以邮件方式送达全体董事。本次会议应出席董事 9 名，实际出席会议董事 9 名。会议由公司董事长兼总经理蔡彤先生主持，全体高级管理人员列席了会议。 本次会议的召集和召开符合《中华人民共和国公司法》（以下简称"《公司法》"） 和《公司章程》的有关规定。 会议采取记名投票的方式进行表决，经与会的董事充分讨论与审议，会议形成 以下决议： 表决结果：赞成9票；反对0票；弃权0票。 本议案尚需提交公司股东会审议。 二、审议通过了《关于制定<信息披露暂缓与豁免管理制度>的议案》 为规范公司及其他信息披露义务人的信息披露暂缓与豁免行为，确保公司依法 合规履行信息披露义务，切实保护公司、股东及投资者的合法权益 ...

雅本化学股份有限公司 信息披露暂缓与豁免管理制度 第一章 总则 第一条 为规范雅本化学股份有限公司（以下简称"公司"）及其他信息披 露义务人的信息披露暂缓与豁免行为，确保公司依法合规履行信息披露义务， 切实保护公司、股东及投资者的合法权益，维护资本市场公开、公平、公正原 则，根据《中华人民共和国公司法》《中华人民共和国证券法》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》《上市公司信息披露暂缓与豁免管理规定》等法 律、行政法规、部门规章、规范性文件以及《公司章程》的有关规定，并结合 公司实际情况，制定本制度。 第二条 公司和其他信息披露义务人暂缓、豁免披露临时报告，在定期报告、 临时报告中豁免披露中国证券监督管理委员会和深圳证券交易所（以下简称 "深交所"）规定或者要求披露的内容，适用本制度。 第三条 公司和其他信息披露义务人应当真实、准确、完整、及时、公平地 披露信息，不得滥用暂缓或者豁免披露规避信息披露义务、误导投资者，不得 实施内幕交易、操纵市场等违法行为。 第四条 公司和其他信息披露义务人应审慎确定信息披露暂缓、豁免事项， 履行内容审 ...

雅本化学股份有限公司 董事、高级管理人员薪酬管理制度 第一章 总则 第一条 为规范雅本化学股份有限公司（以下简称"公司"）董事、高级管 理人员薪酬管理，建立科学有效的激励与约束机制，有效调动公司董事和高级管 理人员的工作积极性和创造性，提高公司的经营管理效率，切实维护公司及股东 权益。根据《中华人民共和国公司法》《上市公司治理准则》等有关法律法规、 规范性文件及《雅本化学股份有限公司章程》（以下简称"《公司章程》"）， 制定本制度。 第二条 本制度适用于下列人员： （一）董事，包括非独立董事、独立董事、职工代表董事； 第三条 公司董事、高级管理人员薪酬管理遵循以下原则： （一）公平原则，体现收入水平符合公司规模与业绩的原则，同时兼顾市 场薪酬水平； （二）责、权、利统一原则，体现薪酬与岗位价值高低、履行责任义务大 小相符； （三）长远发展原则，体现薪酬与公司持续健康发展的目标相符； （二）高级管理人员，包括公司总经理、副总经理、董事会秘书、财务总 监及公司董事会认定的其他人员。 （四）激励约束并重原则，体现薪酬发放与考核、奖惩挂钩，与激励机制 挂钩。 第二章 董事、高级管理人员薪酬管理机构 第四条 公司董事、 ...

Core Viewpoint - NMN (β-Nicotinamide Mononucleotide) is gaining attention in the global health industry for its potential anti-aging, DNA repair, and metabolic regulation benefits, with significant developments in regulatory approval and market potential expected by 2025 [1][2]. Industry Development - The NMN industry has evolved from laboratory research to commercial applications, with major markets like the US, Japan, Canada, and Australia recognizing its legal status through various regulatory pathways [1][2]. - China is currently the largest producer of NMN raw materials, with leading companies building competitive barriers through technological innovation and industry chain layout [2]. NMN Definition and Function - NMN is a direct precursor to NAD+ (Nicotinamide Adenine Dinucleotide), crucial for delaying aging and enhancing physiological functions [3][4]. - Supplementing NMN can quickly elevate NAD+ levels in the body, playing a vital role in anti-aging, cardiovascular health, and metabolic improvement [4]. Synthesis Pathways - NMN supplementation shows significant advantages in NAD+ synthesis pathways compared to other precursors, with the highest conversion efficiency and no known adverse effects [6][7]. Natural Sources and Supplementation - Natural food sources of NMN are limited, making NMN supplements, which can provide up to 300 times the intake from dietary sources, more effective [8]. Synthesis Technology - The NMN synthesis process has shifted from chemical methods to fully enzymatic methods, which are safer, more efficient, and environmentally friendly [10][11]. - Leading companies are innovating in full enzymatic synthesis technology, creating competitive advantages through patent applications [12]. Market Trends and Drivers - The demand for NMN is driven by an aging population and increasing awareness of anti-aging among younger demographics, creating a dual market push [19]. - Technological advancements in synthesis, quality testing, and delivery methods are driving the NMN industry towards scale, standardization, and efficiency [21][22]. Application Areas - NMN is primarily used in health supplements and cosmetics, with potential future applications in pet nutrition, medical health, and agricultural technology [24][28]. - The NMN market in China is expected to exceed 3 billion yuan by 2025, with significant growth anticipated as regulatory barriers are lifted [28]. Sales Channels - NMN products are mainly sold through cross-border e-commerce and private channels, with cross-border platforms accounting for 60%-70% of market share [35]. Certification and Compliance - The "blue hat" certification for health supplements in China represents the highest standard for NMN products, with strict approval processes that could reshape the market landscape if achieved [37]. Challenges and Opportunities - The NMN industry faces challenges such as exaggerated claims, lack of consumer awareness, and technological iterations, necessitating compliance and innovation for long-term competitiveness [61][63]. - Companies are encouraged to innovate their business models, extending from raw material supply to comprehensive service providers across the entire industry chain [66].

Core Viewpoint - NMN (β-Nicotinamide Mononucleotide) is gaining attention in the global health industry for its potential anti-aging, DNA repair, and metabolic regulation benefits, with significant advancements in regulatory approval and market potential expected by 2025 [1][2]. Industry Development - The NMN industry has evolved from laboratory research to commercial applications, with major markets like the US, Japan, Canada, and Australia recognizing its legal status through various regulatory pathways [1][2]. - China is currently the largest producer of NMN raw materials, with leading companies building competitive barriers through technological innovation and industry chain layout [2]. NMN Definition and Function - NMN is a direct precursor to NAD+ (Nicotinamide Adenine Dinucleotide), crucial for delaying aging and enhancing physiological functions [3][4]. - Supplementing NMN can rapidly increase NAD+ levels in the body, playing a vital role in anti-aging, cardiovascular health, and metabolic improvement [4]. Synthesis Pathways - NMN supplementation shows significant advantages in NAD+ synthesis pathways compared to other precursors, with the highest conversion efficiency and no known adverse reactions [6][7]. Natural Sources and Supplementation - Natural food sources of NMN are limited, with dietary intake often insufficient to meet effective dosage levels; NMN supplements provide a much higher intake efficiency [8]. Synthesis Technology - The NMN synthesis process has shifted from chemical methods to fully enzymatic methods, focusing on high purity, safety, and environmental sustainability [10][12]. - Leading companies are innovating in full enzyme technology, establishing patents to create competitive advantages in the NMN market [12]. Market Trends and Applications - NMN is primarily used in health supplements and cosmetics, with potential expansion into pet nutrition, medical health, and agricultural technology [24][28]. - The NMN market in China is expected to exceed 3 billion yuan by 2025, driven by policy relaxation and new applications [28]. Sales Channels - NMN products are mainly sold through cross-border e-commerce and private channels, with cross-border platforms accounting for 60%-70% of market share [35]. Certification and Compliance - The "blue hat" certification for health supplements in China represents the highest standard for NMN products, with strict approval processes impacting market dynamics [37]. Future Prospects - The NMN industry is poised for growth, with increasing demand driven by an aging population and younger consumers seeking anti-aging solutions [19][21]. - Technological advancements in synthesis, quality control, and delivery methods are expected to enhance NMN's market position [21][22]. Challenges - The NMN industry faces challenges related to regulatory compliance, market education, and technological advancements, necessitating a collaborative approach among stakeholders [61][63].

公司于近日收到众华出具的《关于变更雅本化学股份有限公司签字注册会计师 的函》，具体情况公告如下： 证券代码：300261 证券简称：雅本化学 公告编号：2026-014 雅本化学股份有限公司 关于变更签字注册会计师的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 雅本化学股份有限公司（以下简称"公司"）于 2025 年 4 月 21 日召开第六届 董事会第二次会议，审议通过了《关于续聘会计师事务所的议案》，同意续聘众华 会计师事务所（特殊普通合伙）（以下简称"众华"）为 2025 年度财务审计和内部 控制审计机构。具体内容详见公司 2025 年 4 月 23 日在巨潮资讯网披露的《关于续 聘 2025 年度会计师事务所的公告》（公告编号：2025-036）。上述议案于 2025 年 5 月 13 日经公司 2024 年年度股东大会审议通过。 注册会计师，2016 年成为注册会计师、2009 年开始从事上市公司审计、至今参 与或负责多家上市公司年度审计，2025 年开始在众华会计师事务所（特殊普通合伙） 一、签字注册会计师变更情况 众华作为公司2025年度 ...

Core Viewpoint - NMN (β-Nicotinamide Mononucleotide) is gaining attention in the global health industry for its potential anti-aging, DNA repair, and metabolic regulation benefits, with significant advancements in regulatory approval and market potential expected by 2025 [1][2]. Group 1: NMN Definition and Function - NMN is a direct precursor to NAD+ (Nicotinamide Adenine Dinucleotide), crucial for delaying aging and enhancing physiological functions [3][4]. - Supplementing NMN can rapidly increase NAD+ levels in the body, playing a vital role in anti-aging, cardiovascular health, metabolism, and cognitive function [4][6]. Group 2: NMN Industry Development - The NMN industry has evolved from scientific research to commercialization, with significant milestones achieved in various countries, including Japan, the U.S., and Australia, which have recognized NMN's legal status [1][15]. - China is currently the largest producer of NMN raw materials, with key companies building competitive barriers through technological innovation and industry chain layout [2][32]. Group 3: Regulatory Environment - The global regulatory landscape for NMN is shifting from strict restrictions to cautious openness, with China making strides in legalizing NMN for cosmetic and health food applications [17][18]. - As of April 2025, NMN has been included in China's health food approval list, indicating a positive trend towards regulatory acceptance [17][18]. Group 4: Market Demand - The aging population in China is expected to drive the "silver economy," with the elderly population projected to grow from 320 million to 390 million between 2025 and 2030, creating a substantial market for anti-aging products [19]. - Younger generations, particularly those born in the 1990s, are increasingly aware of anti-aging needs, further boosting market demand for NMN products [19]. Group 5: Technological Innovations - Advances in NMN synthesis methods, particularly the full enzyme method, have significantly improved production efficiency and reduced costs, driving industry upgrades [21][22]. - Innovations in delivery technologies are enhancing the bioavailability and user experience of NMN products, ensuring effective absorption [22]. Group 6: Application Areas - NMN is primarily used in health supplements and cosmetics, with the health supplement market accounting for nearly 90% of its applications [24][28]. - Future applications are expected to expand into pet nutrition, medical health, and agricultural technology, opening new growth avenues [24][28]. Group 7: Market Size and Growth - The NMN market in China is anticipated to exceed 3 billion yuan by 2025, driven by increasing regulatory acceptance and research breakthroughs in various application areas [28][32]. Group 8: Sales Channels - NMN products are primarily sold through cross-border e-commerce and private channels, with cross-border e-commerce accounting for 60%-70% of market share [35]. Group 9: Certification and Standards - The "blue hat" certification for health foods in China represents the highest standard for NMN products, indicating safety and compliance [37]. Group 10: Challenges and Opportunities - The NMN industry faces challenges such as exaggerated claims, lack of awareness, and technological iterations, necessitating a focus on compliance and innovation to unlock market potential [61][63].

二、担保的进展情况 证券代码：300261 证券简称：雅本化学 公告编号：2026-013 雅本化学股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、担保情况概述 2026 年 1 月 26 日，雅本化学股份有限公司（以下简称"公司"）第六届 董事会第八次（临时）会议审议通过了《关于公司为子公司提供担保及子公司 互相担保的议案》。为满足子公司的经营发展需要，公司同意为全资子公司南 通雅本化学有限公司（以下简称"南通雅本"）办理银行授信等业务提供担保。 具体内容详见公司于 2026 年 1 月 28 日在巨潮资讯网上披露的《关于公司为子 公司提供担保及子公司互相担保的公告》（公告编号：2026-006）。2026 年 2 月 12 日，公司 2026 年第一次临时股东会审议通过了上述议案。 2025 年 6 月 16 日，公司第六届董事会第四次（临时）会议和第六届监事 会第四次（临时）会议审议通过了《关于全资子公司向银行申请项目贷款并由 公司提供担保的议案》，公司同意为南通雅本申请银行项目贷款提供担保，担 保方式为连带 ...

Group 1 - The core point of the article is that Yabao Chemical (300261) reported a total of 51,876 shareholders as of February 10, 2026 [1]